Arcoxia “approvable” but delayed in US

Nov 1, 2007 Rockville, MD - The US FDA has deemed that the new selective COX-2 inhibitor etoricoxib (Arcoxia, Merck & Co) is “approvable” but that additional data on rubber manoeuvre and efficacy are required before the liking can be granted.
This is the company’s agreement coxib, pursual on from rofecoxib (Vioxx), which it voluntarily withdrew from the mercantile formation a few weeks ago.
Etoricoxib is already available in some other parts of the world
This is a part of article Arcoxia “approvable” but delayed in US Taken from "Etoricoxib Arcoxia" Information Blog